Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sorry, but i've seen this pelicula many times. Usually a delay doesn't mean what the board thinks it does (partnership, fast-track, etc.).
That goes without saying. The question is: who do the odds favor?
wait until Saturday and you just might.
Not new. Anson.
uh, he's had months to do that already and he hasn't. Why not?
Show of hands: Who thought the share price would be around 4.00 three days before big event?
if anyone has just thought for a second they would have known that it wasn't ONCS. SI is like 4% or something, no "heavily shorted" by any means.
A road show wouldn't be necessary if a company didn't have to convince, imo.
who cares?
Road shows mean nothing. Publicity stunts. CTAD is important...according to board. No price movement bodes well? (If someone had taken a poll on this board two or three weeks ago asking what the share price would be around Nov.1, I am sure most posters would have said higher than it is now. Disconcerting, if you ask me. Missling will probably repeat the same bs. What we need is unequivocal efficacy data. Does it work?
Are you crazy? Enrollment hasn't even started! Try 2020.
uh, i think you forgot the other scenario.
Guys, shouldn't this, like, be a lot higher, going into CTAD presentation? Just saying.
of course not. After the great news the share price will be supported. Yah, right! And you make a good point, esp. if no trial has begun before then. Time and money will be against the share price. Period.
Nothing means nothing. Data mean everything. Enough! Let's see data update. Seems the board has decided to ignore this little catalyst promise.
Would be REALLY interesting to know what Merck thinks about Oncosec and its science.
speaking of simply not true...
into mid-2018 should be fine. I worry a bit between then--the typical trading pattern. But maybe tutes will use this time to accumulate. Could be huge pay-back, in long run.
that, for him, is saying a lot. I like that "definitely."
Agreed. I like the way Pete thinks.
Wasted post. It doesn't. I want to see unequivocal data that confirm efficacy. Anything wrong with that?
it's a shame we are still in the dark as to the certainty of the data. Why? What hasn't it been made clear? (And, obviously, it isn't clear for the Street either.). What's going go?
Bottom line: no credibility. We'll see what happens in two weeks, but, contrary to AAIC, I have not bought any calls (I learned my lesson, at least with AVXL).
Agreed. Getting old. Reason the pps is where it is. Nobody is willing to bet on ambiguous data. More so when the company does nothing--concrete--to corroborate data. We'll see what happens at the upcoming conference. Nothing but rehashed data will destroy the stock.
Xena, we agree on something. Kudos.
Sorry, didn't catch that. Thanks for the truth.
Maybe Missling knows how to say the truth in German.
I mean, seriously, what is there to hold the bottom up? No data. Kind of like silence digging its own hole.
as always, flash, you make a lot of sense. A voice of reason.
good question.
Agreed.